

Philadelphia's Global Impact...

Decades of Innovation in Radiation Therapy




Department of Radiation Oncology

For decades, the Fox Chase Cancer Center Department of Radiation Oncology has earned a reputation for clinical excellence, pioneering clinical trials, and a willingness to move sophisticated ideas to the brink of discovery, impacting physicians and scientists globally.

At the helm is Eric Horwitz, MD, FABS, FASTRO, Chair of the Department of Radiation Oncology at Fox Chase and the Lewis Katz School of Medicine at Temple University. Dr. Horwitz's bold vision has quickly brought breakthrough technology such as FDA-approved Adaptive Radiation Therapy (ART) into the mainstream, demonstrating its superior clinical precision for many cancers.

Fox Chase is now one of the few national and regional leaders offering vast experience in ART clinical care and innovative clinical trials—exactly fulfilling the the mission of a National Cancer Institute-designated Comprehensive Cancer Center.



State-of-the-Art Therapy

Adaptive Radiation Therapy, high-dose-intensity modulated radiation therapy (IMRT), and low-dose-rate (LDR) brachytherapy, among many others.



Clinical Excellence

Subspecialist oncologist expertise for breast, lung, gastrointestinal, genitourinary, and prostate cancers.



Elite Residency Training

A radiation oncology residency program that has trained the best and brightest for over 40 years.



Research Discovery and Delivery

Developed many now-standard treatments, including 3D conformal radiation therapy.



NCI-designated Comprehensive Cancer Center

For over 50 years, only 52 in the country.

Adaptive Radiation Clinical Trials

We Discover. We Deliver.



Below is a list of adaptive radiation clinical trials that are currently open at Fox Chase Cancer Center. For more information about these studies, please call **215-214-1515** or visit **[FoxChase.org/ClinicalTrials](https://www.FoxChase.org/ClinicalTrials)**.

Adaptive Radiation for Abdominopelvic Metastases (ARAM)



STUDY SUMMARY: Single-arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.

PROTOCOL: 23-1012 / IRB23-1012 **INVESTIGATOR:** Joshua E. Meyer, MD, FASTRO

Scan the QR code for study details and eligibility criteria.

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study



STUDY SUMMARY: The goal of this clinical trial is to learn whether Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

The main questions the study aims to answer are:

- Can ART improve how well radiation therapy targets the most aggressive cancer cells while protecting the healthy tissue around the tumor?
- Can ART help reduce the side effects that participants may experience during treatment?

PROTOCOL: 25-1011 / IRB25-1011 **INVESTIGATOR:** Joshua E. Meyer, MD, FASTRO

Scan the QR code for study details and eligibility criteria.

Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Prospective Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix)



STUDY SUMMARY: This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity-modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

PROTOCOL: 23-1025 / IRB23-1025 **INVESTIGATOR:** Jeremy Price, MD, PhD

Scan the QR code for study details and eligibility criteria.

Contact Our Team

Our Key Account Managers can offer a seamless introduction to our specialists, obtain a patient appointment, and answer any questions or concerns you have. Contact our team at **KeyAccountManager@fcc.edu**.

How to Refer

To refer a patient to Fox Chase, please call **888-FOX-CHASE** or visit **[FoxChase.org/Refer](https://www.FoxChase.org/Refer)**.

For international patient referrals, please contact our International Medicine Office at **InternationalMedicine@tuhs.temple.edu**.

 **Fox Chase
Cancer Center**
Temple Health

333 Cottman Avenue | Philadelphia, PA 19111

[FoxChase.org](https://www.FoxChase.org)

Non-discrimination notice: It is the policy of Fox Chase Cancer Center and Temple University Hospital, Inc., that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

© Fox Chase Cancer Center. All rights reserved. 9/25